Navigation Links
Bowel Disease Treatment May Raise Skin Cancer Risk
Date:10/26/2009

Rates of non-melanoma cancer higher in patients with Crohn's, ulcerative colitis, study finds

MONDAY, Oct. 26 (HealthDay News) -- Inflammatory bowel disease (IBD) patients who are being treated with immunosuppressive medications may be at increased risk for non-melanoma skin cancer, a new U.S. study says.

Researchers analyzed data on 26,403 Crohn's disease patients and 26,974 patients with ulcerative colitis in order to evaluate how the use of immunosuppressive and biologic medications to treat IBD affected non-melanoma skin cancer risk.

The study found that the incidence of non-melanoma skin cancer was higher in IBD patients than in a control group. Recent use (within 90 days) of any immunosuppressive medication was associated with greater risk of non-melanoma skin cancer (adjusted odds ratio 3.28), as was recent use of the thiopurine class of immunosuppressive medications (adjusted odds ratio 3.56) and recent use of biologic medications in Crohn's disease patients (adjusted odds ratio 2.07).

Persistent use of any immunosuppressive medication, which was considered use for over one year, was strongly associated with non-melanoma skin cancer (adjusted odds ratio 4.04), the study authors noted. The association was even stronger with persistent use of thiopurine medications (adjusted odds ratio 4.27). In Crohn's disease, persistent use of biologic medications was also associated with a raised risk (adjusted odds ratio 2.18).

"The increased risk of [non-melanoma skin cancer] in patients with IBD is likely related to the immunosuppressive medications used to treat the disease, although we can't rule out changes to the immune system itself as a result of IBD as contributing to this risk," said study leader Dr. Millie Long, of the University of North Carolina at Chapel Hill.

"In patients on immunosuppression therapy after organ transplant, previous studies have shown a clear association with [non-melanoma skin cancer]. Other studies have demonstrated that azathioprine, which is in the thiopurine class, can increase the photosensitization of human skin," she noted.

Long concluded that the study "demonstrates that patients with IBD on immunosuppression may also be at risk for [non-melanoma skin cancer]. As a result, our long-term management plans for IBD patients should stress the daily use of broad-spectrum sunscreen and increased awareness of [non-melanoma skin cancer] to help to prevent complications."

The study was scheduled to be presented this week at the annual scientific meeting of the American College of Gastroenterology, in San Diego.

More information

The American Academy of Family Physicians has more about inflammatory bowel disease.



-- Robert Preidt



SOURCE: American College of Gastroenterology, news release, Oct. 26, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Elsevier announces new journal on inflammatory bowel diseases
2. C-diff infection 4 times more likely to kill patients with inflammatory bowel disease
3. Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients
4. Threshold for bowel surgery may be too high, warn experts
5. Antegrade bowel intussusception can cause recurrent, chronic postoperative intestinal obstruction
6. Bowel cancer screening halves emergency admissions and cuts deaths
7. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
8. Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals
9. Allergic disease linked to irritable bowel syndrome
10. Abuse history affects pain regulation in women with irritable bowel syndrome
11. Harnessing the Mind to Manage Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: